RA Capital (NASDAQ: COAG) funds add Hemab Therapeutics shares in open-market purchases
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Hemab Therapeutics Holdings, Inc. disclosed that investment vehicles associated with RA Capital made open-market purchases of its Common Stock. On May 19, an RA Capital-related entity bought 3,802 shares at a weighted average price of $24.97 per share, and on May 20 another purchase of 996 shares was made at a weighted average price of $24.94 per share. Following these transactions, RA Capital-affiliated entities indirectly held 6,376,968 shares of Hemab Therapeutics Common Stock. The filing notes that shares are held directly by RA Capital Healthcare Fund, L.P. and RA Capital Nexus funds, and that the Adviser, its general partner, and principals disclaim beneficial ownership of the reported securities except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 4,798 shares ($119,776)
Net Buy
4 txns
Insider
RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M.
Role
null | null | null | null
Bought
4,798 shs ($120K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 996 | $24.94 | $25K |
| Purchase | Common Stock | 3,802 | $24.97 | $95K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 6,376,968 shares (Indirect, See footnotes)
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.86 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II") and RA Capital Nexus IV Fund, L.P. (the "Nexus Fund IV"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Held directly by the Fund. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.85 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Held directly by Nexus Fund II. Held directly by Nexus Fund IV.
Key Figures
Shares bought May 19: 3,802 shares
Shares bought May 20: 996 shares
Total shares bought: 4,798 shares
+3 more
6 metrics
Shares bought May 19
3,802 shares
Open-market purchase of Common Stock at weighted average $24.97
Shares bought May 20
996 shares
Open-market purchase of Common Stock at weighted average $24.94
Total shares bought
4,798 shares
Net buy across reported transactions
Indirect holdings after trades
6,376,968 shares
Total Hemab Therapeutics Common Stock held indirectly post-transaction
Nexus II holdings
354,938 shares
Common Stock held indirectly as of May 19
Nexus IV holdings
1,009,052 shares
Common Stock held indirectly as of May 19
Key Terms
open-market purchase, weighted average price, ten percent owner, indirect ownership, +1 more
5 terms
open-market purchase financial
"transaction_action: "open-market purchase" for Common Stock on May 19 and May 20"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
ten percent owner financial
"is_ten_percent_owner": 1 for several reporting persons"
indirect ownership financial
"ownership_type": "indirect" and direct_or_indirect": "I" for the transactions"
pecuniary interest financial
"disclaim beneficial ownership ... except to the extent of their pecuniary interest therein."
FAQ
What insider transactions did RA Capital report in Hemab Therapeutics (COAG)?
RA Capital-affiliated entities reported open-market purchases of Hemab Therapeutics Common Stock totaling 4,798 shares. The trades occurred on May 19 and May 20, increasing their indirect holdings to 6,376,968 shares after the transactions.
Do RA Capital and its principals claim full beneficial ownership of Hemab Therapeutics (COAG) shares?
No. The filing states that RA Capital Management, its general partner, RA Capital Healthcare Fund, and principals disclaim beneficial ownership of the reported Hemab Therapeutics securities, except to the extent of their pecuniary interest in those fund-held positions.